Harnessing Antitumor CD4 T Cells for Cancer Immunotherapy.

Cancers (Basel)

UMR1098, EFS BFC, INSERM, Interactions Hôte-Greffon-Tumeur/Ingénierie Cellulaire et Génique, University of Bourgogne Franche-Comté, F-25000 Besançon, France.

Published: January 2022

Over the past decades, CD4 T cells have been considered as a supporting actor in the fields of cancer immunotherapy. Until recently, accumulating evidence has demonstrated the critical role of CD4 T cells during antitumor immunity. CD4 T cells can either suppress or promote the antitumor cytotoxic CD8 T cell responses, either in secondary lymphoid organs or in the tumor. In this review, we provide an overview of the multifaceted role of different CD4 T cell subsets in cancer immune response and their contribution during cancer therapies. Specifically, we focus on the latest progress regarding the impact of CD4 T cell modulation on immunotherapies and other cancer therapies and discuss the prospect for harnessing CD4 T cells to control tumor progression and prevent recurrence in patients.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8750687PMC
http://dx.doi.org/10.3390/cancers14010260DOI Listing

Publication Analysis

Top Keywords

cd4 cells
20
cancer immunotherapy
8
role cd4
8
cd4 cell
8
cancer therapies
8
cd4
7
cells
5
cancer
5
harnessing antitumor
4
antitumor cd4
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!